Selective Vitamin D Receptor Activation as Anti-Inflammatory Target in Chronic Kidney Disease

• Autors principals: J. Donate-Correa (Autor), V. Domínguez-Pimentel (Autor), M. L. Méndez-Pérez (Autor), M. Muros- (Autor), C. Mora-Fernández (Autor), E. Martín-Núñez (Autor), V. Cazaña-Pérez (Autor), J. F. Navarro-González (Autor)
• Format: Llibre
• Publicat: Hindawi Limited, 2014-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Paricalcitol, a selective vitamin D receptor (VDR) activator used for treatment of secondary hyperparathyroidism in chronic kidney disease (CKD), has been associated with survival advantages, suggesting that this drug, beyond its ability to suppress parathyroid hormone, may have additional beneficia...